Breaking News
Get 40% Off 0
Join +750K new investors every month who copy stock picks from billionaire's portfolios Sign Up Free
Close

Axa Spdb Value Growth Equity A (519110)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.975 +0.010    +0.99%
14/06 - Closed. Currency in CNY ( Disclaimer )
  • Morningstar Rating:
  • Total Assets: 491.87M
Type:  Fund
Market:  China
Issuer:  AXA SPDB Investment Managers Co.,Ltd
Asset Class:  Equity
AXA SPDB Value Growth Equity A 0.975 +0.010 +0.99%

519110 Holdings

 
Comprehensive information about top holdings and Key Holding Information for the AXA SPDB Value Growth Equity A (519110) fund. Our AXA SPDB Value Growth Equity A portfolio information includes stock holdings, annual turnover, top 10 holdings, sector and asset allocation.

Asset Allocation

Create Alert
Add to Watchlist
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Name  Net %  Long %  Short %
Cash 18.480 18.480 0.000
Shares 82.770 82.770 0.000

 Style Box

Value & Growth Measures

Ratios Value Category Average
P/E Ratio 18.536 15.184
Price to Book 3.047 1.983
Price to Sales 2.355 1.416
Price to Cash Flow 13.548 7.778
Dividend Yield 1.014 2.262
5 Years Earnings Growth 23.787 18.479

Sector Allocation

Name  Net % Category Average
Technology 28.890 18.768
Healthcare 28.040 9.027
Industrials 15.240 24.384
Consumer Cyclical 13.790 15.068
Basic Materials 8.000 17.837
Consumer Defensive 6.040 5.144

Region Allocation

  • Asia
  • Emerging Markets

Top Holdings

Number of long holdings: 83

Number of short holdings: 1

Name ISIN Weight % Last Change %
  Luxshare Precision A CNE100000TP3 4.30 34.35 +3.37%
  Suzhou Shijing Environmental Technology Co CNE100004N83 4.18 29.86 -2.32%
  Chongqing Taiji Industry CNE000000TQ2 4.11 35.56 -1.77%
  Suzhou Maxwell CNE100003FS0 4.04 136.08 -5.58%
  Chongqing Zhifei Bio Products CNE100000V20 3.82 30.41 -1.59%
  Jiangsu Pacific Precision CNE1000016K5 3.57 8.79 -1.35%
  Shenyang Xingqi Pharma CNE100002DV1 3.50 186.85 -4.03%
  Shenzhen Sunway Communication CNE100000W94 3.41 18.23 +1.11%
  Humanwell Healthcare CNE000000QW6 3.29 18.68 -1.16%
  JCHX Mining Management CNE1000022P2 3.07 51.96 +0.23%

Top Equity Funds by AXA SPDB Investment Managers Co.,Ltd

  Name Rating Total Assets YTD% 3Y% 10Y%
  AXA SPDB Consumption Upgrade Allo A 1.5B -8.55 -6.75 8.96
  AXA SPDB Consumption Upgrade Allo C 1.5B -8.63 -6.93 -
  AXA SPDB Dividend Selected Stock 849.55M -14.67 -6.97 10.90
  AXA SPDB CSI 300 Index Strengthen F 578.59M 6.18 -10.88 9.74
  AXA SPDB Growth flexible allocate 545.58M -14.81 -13.32 -
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

519110 Comments

Write your thoughts about Axa Spdb Value Growth Equity A
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email